CN112274648A - 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 - Google Patents
一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 Download PDFInfo
- Publication number
- CN112274648A CN112274648A CN202011318698.3A CN202011318698A CN112274648A CN 112274648 A CN112274648 A CN 112274648A CN 202011318698 A CN202011318698 A CN 202011318698A CN 112274648 A CN112274648 A CN 112274648A
- Authority
- CN
- China
- Prior art keywords
- solution
- organic framework
- metal organic
- minutes
- cholesterol oxidase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011318698.3A CN112274648B (zh) | 2020-11-23 | 2020-11-23 | 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011318698.3A CN112274648B (zh) | 2020-11-23 | 2020-11-23 | 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112274648A true CN112274648A (zh) | 2021-01-29 |
CN112274648B CN112274648B (zh) | 2022-10-14 |
Family
ID=74425063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011318698.3A Active CN112274648B (zh) | 2020-11-23 | 2020-11-23 | 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112274648B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114163481A (zh) * | 2021-12-06 | 2022-03-11 | 郑州大学 | 一种含铂类药物纳米囊泡及其制备方法与应用 |
CN114409914A (zh) * | 2022-01-12 | 2022-04-29 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | MOF-On-MOF架构的铁基金属有机框架复合材料的制备方法及所得产品和应用 |
CN114539545A (zh) * | 2022-01-13 | 2022-05-27 | 中国科学院宁波材料技术与工程研究所 | 一种双金属-有机框架材料及其制备方法和应用 |
CN114712304A (zh) * | 2022-04-18 | 2022-07-08 | 深圳大学 | 海藻酸钠基复合水凝胶的制备方法 |
CN116083411A (zh) * | 2023-03-23 | 2023-05-09 | 北京理工大学 | 一种非均相光-酶偶联催化剂、制备方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1255864A (zh) * | 1997-03-11 | 2000-06-07 | G·D·瑟尔公司 | 使用回肠胆汁酸传输抑制苯并硫杂环庚三烯和HMGCo-A还原酶抑制剂的组合疗法 |
CN104984341A (zh) * | 2015-07-22 | 2015-10-21 | 郑州大学 | 一种近红外激光触发的复合纳米制剂的制备方法 |
WO2017049411A1 (en) * | 2015-09-23 | 2017-03-30 | University Health Network | Methods, compounds and compositions for modulating blood brain barrier integrity and re-myelination |
-
2020
- 2020-11-23 CN CN202011318698.3A patent/CN112274648B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1255864A (zh) * | 1997-03-11 | 2000-06-07 | G·D·瑟尔公司 | 使用回肠胆汁酸传输抑制苯并硫杂环庚三烯和HMGCo-A还原酶抑制剂的组合疗法 |
CN104984341A (zh) * | 2015-07-22 | 2015-10-21 | 郑州大学 | 一种近红外激光触发的复合纳米制剂的制备方法 |
WO2017049411A1 (en) * | 2015-09-23 | 2017-03-30 | University Health Network | Methods, compounds and compositions for modulating blood brain barrier integrity and re-myelination |
Non-Patent Citations (3)
Title |
---|
BIN DU ET AL: "Nanozyme‑natural enzymes cascade catalyze cholesterol consumption and reverse cancer multidrug resistance", 《JOURNAL OF NANOBIOTECHNOLOGY》 * |
JAVAD HASSANZADEH ET AL: "Encapsulated cholesterol oxidase in metal-organic framework andbiomimetic Ag nanocluster decorated MoS2nanosheets for sensitivedetection of cholesterol", 《SENSORS AND ACTUATORS B: CHEMICAL》 * |
陈敦富: "胆固醇氧化酶最新研究进展", 《生物技术》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114163481A (zh) * | 2021-12-06 | 2022-03-11 | 郑州大学 | 一种含铂类药物纳米囊泡及其制备方法与应用 |
CN114163481B (zh) * | 2021-12-06 | 2023-06-23 | 郑州大学 | 一种含铂类药物纳米囊泡及其制备方法与应用 |
CN114409914A (zh) * | 2022-01-12 | 2022-04-29 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | MOF-On-MOF架构的铁基金属有机框架复合材料的制备方法及所得产品和应用 |
CN114539545A (zh) * | 2022-01-13 | 2022-05-27 | 中国科学院宁波材料技术与工程研究所 | 一种双金属-有机框架材料及其制备方法和应用 |
CN114712304A (zh) * | 2022-04-18 | 2022-07-08 | 深圳大学 | 海藻酸钠基复合水凝胶的制备方法 |
CN114712304B (zh) * | 2022-04-18 | 2024-03-12 | 深圳大学 | 海藻酸钠基复合水凝胶的制备方法 |
CN116083411A (zh) * | 2023-03-23 | 2023-05-09 | 北京理工大学 | 一种非均相光-酶偶联催化剂、制备方法及其应用 |
CN116083411B (zh) * | 2023-03-23 | 2023-06-27 | 北京理工大学 | 一种非均相光-酶偶联催化剂、制备方法及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112274648B (zh) | 2022-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112274648B (zh) | 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法 | |
Huang et al. | New advances in gated materials of mesoporous silica for drug controlled release | |
Ramachandran et al. | Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery | |
CN109364267B (zh) | 肿瘤组织和细胞双重靶向的介孔二氧化硅纳米载药颗粒及其制备方法 | |
Song et al. | Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced | |
CN103110955B (zh) | 纳米药物载体、还原响应的纳米药物颗粒与纳米药物颗粒制剂及其制备方法 | |
EP1802295B1 (en) | Oral pharmaceutical composition for targeted transport of a platinum complex into the colorectal region, method for producing and use as medicament thereof | |
CN108178803B (zh) | 一种载药的肉桂醛-葡聚糖聚合物自组装纳米粒的制备及其抗肿瘤应用 | |
Wu et al. | PDA-based drug delivery nanosystems: a potential approach for glioma treatment | |
Ma et al. | Designing colon‐specific delivery systems for anticancer drug‐loaded nanoparticles: An evaluation of alginate carriers | |
Ehsanimehr et al. | Synthesis of pH-sensitive nanocarriers based on polyacrylamide grafted nanocrystalline cellulose for targeted drug delivery to folate receptor in breast cancer cells | |
US8282944B2 (en) | Metal complexes incorporated within biodegradable nanoparticles and their use | |
Pan et al. | Hyaluronic a cid–doxorubicin nanoparticles for targeted treatment of colorectal cancer | |
CN101708337B (zh) | 一种包载奥沙利铂的人血白蛋白纳米粒的制备方法 | |
Baig et al. | PLL-alginate and the HPMC-EC hybrid coating over the 3D DNA nanocubes as compact nanoparticles for oral administration | |
Zhang et al. | The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics | |
Zhu et al. | PLGA nanoparticles delivering CPT-11 combined with focused ultrasound inhibit platinum resistant ovarian cancer | |
CN114748644B (zh) | 一种以zif-8为基质的藻蓝蛋白分子印迹药物载体的制备方法 | |
Zhang et al. | Co-delivery of sorafenib and metformin from amphiphilic polypeptide-based micelles for colon cancer treatment | |
JP2006521300A (ja) | 活性物質として白金錯体を含有する医薬組成物およびその製造方法 | |
Patel et al. | Characterization of calcium alginate beads of 5-fluorouracil for colon delivery | |
CN114470239A (zh) | 一种聚多巴胺包覆的缓释型MnO2纳米微球载药系统 | |
CN109666087B (zh) | 一种环糊精类衍生物及其制备方法与应用 | |
JP2022543024A (ja) | ドラッグキャリアシステムとして用いられる、デキストランでコートされたシリカエアロゲル、及びデキストランでコートされたシリカエアロゲルの製造方法 | |
CN101690820B (zh) | 载有铂类药物的纳米微球和其被天然高分子包裹的水凝胶及其制法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Du Bin Inventor after: Yu Lili Inventor after: Huang Jingshu Inventor after: Zheng Mei Inventor after: Wang Yuehua Inventor after: Ma Huizhen Inventor after: Bai Yimeng Inventor after: Jiao Qingqing Inventor after: Zhao Mengmeng Inventor after: Pang Mengxue Inventor before: Du Bin Inventor before: Yu Lili Inventor before: Huang Jingshu Inventor before: Zheng Mei Inventor before: Wang Yuehua Inventor before: Ma Huizhen Inventor before: Bai Yimeng Inventor before: Jiao Qingqing Inventor before: Zhao Mengmeng Inventor before: Pang Mengxue |
|
GR01 | Patent grant | ||
GR01 | Patent grant |